NCT01801423 (SPIN) is a NA clinical trial of Hydroxyurea in Sickle Cell Anemia, sponsored by Vanderbilt University Medical Center.

Who is sponsoring NCT01801423?

NCT01801423 is sponsored by Vanderbilt University Medical Center.

What drugs are being tested in NCT01801423?

Interventions in NCT01801423: Hydroxyurea.

What condition does NCT01801423 study?

NCT01801423 studies Sickle Cell Anemia, Sickle Cell Disease, Stroke.

Is NCT01801423 still recruiting?

NCT01801423 is currently completed. Last updated 3 August 2020.

Last reviewed 2020-08-03 · How we verify

NCT01801423: SPIN

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Sickle Cell Disease - Stroke Prevention in Nigeria Trial

Completed NA Last updated 3 August 2020

What this trial tests

NA trial testing Hydroxyurea in Sickle Cell Anemia in 29 participants. Completed in 31 January 2019.

Timeline

24 April 2013

Primary endpoint
31 January 2019

31 January 2019

Quick facts

Lead sponsor	Vanderbilt University Medical Center
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	29
Start date	24 April 2013
Primary completion	31 January 2019
Estimated completion	31 January 2019
Sites	1 location across Nigeria

Drugs / interventions tested

Hydroxyurea — full drug profile →

Conditions studied

Sickle Cell Anemia — all drugs for Sickle Cell Anemia →
Sickle Cell Disease — all drugs for Sickle Cell Disease →
Stroke — all drugs for Stroke →

Sponsor

Vanderbilt University Medical Center

Who can join

Adults 5 to 12, any sex, with Sickle Cell Anemia or Sickle Cell Disease. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Given large absolute numbers of individuals with sickle cell disease in Nigeria, hydroxyurea therapy for all individuals with sickle cell disease may not be initially feasible; however, a targeted strategy of hydroxyurea use for primary prevention of strokes is an alternative to the standard therapy (observation) for high-risk individuals. The investigators propose a feasibility study, Sickle Cell Disease - Stroke Prevention in Nigeria (SPIN) Trial, to determine whether hydroxyurea can be used for primary prevention of strokes in Nigerian children with sickle cell anemia.

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

Sickle cell anemia in sub-Saharan Africa: advancing the clinical paradigm through partnerships and research.
McGann PT, Hernandez AG, Ware RE. · · 2017 · cited 75× · PMID 27821508 · DOI 10.1182/blood-2016-09-702324
Hydroxyurea for primary stroke prevention in children with sickle cell anaemia in Nigeria (SPRING): a double-blind, multicentre, randomised, phase 3 trial.
Abdullahi SU, Jibir BW, Bello-Manga H, Gambo S, et al · · 2022 · cited 74× · PMID 34971579 · DOI 10.1016/s2352-3026(21)00368-9
Feasibility trial for primary stroke prevention in children with sickle cell anemia in Nigeria (SPIN trial).
Galadanci NA, Umar Abdullahi S, Vance LD, Musa Tabari A, et al · · 2017 · cited 55× · PMID 28439953 · DOI 10.1002/ajh.24770
Moderate fixed-dose hydroxyurea for primary prevention of strokes in Nigerian children with sickle cell disease: Final results of the SPIN trial.
Galadanci NA, Abdullahi SU, Ali Abubakar S, Wudil Jibir B, et al · · 2020 · cited 48× · PMID 32510680 · DOI 10.1002/ajh.25900
Effective use of hydroxyurea for sickle cell anemia in low-resource countries.
Power-Hays A, Ware RE. · · 2020 · cited 45× · PMID 32205588 · DOI 10.1097/moh.0000000000000582
Primary stroke prevention in Nigerian children with sickle cell disease (SPIN): challenges of conducting a feasibility trial.
Galadanci NA, Abdullahi SU, Tabari MA, Abubakar S, et al · · 2015 · cited 35× · PMID 25399822 · DOI 10.1002/pbc.25289
Hydroxyurea for secondary stroke prevention in children with sickle cell anemia in Nigeria: a randomized controlled trial.
Abdullahi SU, Sunusi S, Abba MS, Sani S, et al · · 2023 · cited 31× · PMID 36322937 · DOI 10.1182/blood.2022016620
Associations of transcranial doppler velocity, age, and gender with cognitive function in children with sickle cell anemia in Nigeria.
Prussien KV, Salihu A, Abdullahi SU, Galadanci NA, et al · · 2019 · cited 19× · PMID 30269648 · DOI 10.1080/09297049.2018.1526272

Verify or expand the search:

Other trials of Hydroxyurea

Trials testing the same drug.

NCT06930352 — Ziftomenib for the Treatment of Patients With NPM1 Mutated or KMT2A Rearranged Acute Myeloid Leukemia Not Eligible for S · Phase 2 · not yet recruiting
NCT06871410 — Genetically Engineered Cells (CD83 CAR T Cells) for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia · Phase 1 · recruiting
NCT06526117 — Stroke Prevention in Nigeria 2 Trial · Phase 4 · recruiting
NCT06456346 — Bomedemstat vs Hydroxyurea for Essential Thrombocythemia (MK-3543-007) · Phase 3 · recruiting
NCT05285917 — Promoting Utilization and Safety of Hydroxyurea Using Precision in Africa · Phase 3 · recruiting

Other recruiting trials for Sickle Cell Anemia

Currently open trials in the same condition.

NCT06016634 — Alendronate for Osteonecrosis in Adults With Sickle Cell Disease · Phase 2 · recruiting
NCT07356050 — Verifying Antibodies After Live Immunization Delivery (VALID): A Study of Measles Vaccine Immunogenicity in Children Wit · recruiting
NCT05675436 — Investigating the Mechanistic Effects of Mitapivat in Subjects With Sickle Cell Disease · active not recruiting
NCT06529874 — Pressure Pain Tolerance in Relation to Balance and Strength in Children · NA · recruiting
NCT07116772 — Serial Assessment of Fertility Experiences · recruiting

Other Vanderbilt University Medical Center trials

Trials by the same sponsor.

NCT07005037 — Swallowing Impairments in ICU Survivors and Community-Dwelling Adults · not yet recruiting
NCT07527273 — Cognitive Enhancement in Recurrent Depression (The COG-D-R Study) · NA · not yet recruiting
NCT07295288 — Botox Injections in Non-Cranial Nerve VII Innervated Muscles for Facial Synkinesis · Phase 4 · not yet recruiting
NCT07431541 — Topical Carboxytherapy Paste Following Microneedling · Phase 1, PHASE2 · not yet recruiting
NCT07224711 — The Impact of Perioperative Lidocaine Infusions on Enhanced Recovery After Non-Cardiac Surgery · Phase 4 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT01801423 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Vanderbilt University Medical Center
Last refreshed: 3 August 2020

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT01801423.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing